MedTrace Logo

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

NCT00631527 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2015-01-29

No results posted yet for this study

Summary

The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer.

Conditions

Interventions

DRUG

Leuprolide

Injections given through a needle in the muscle every 3 months.

DRUG

Goserelin

Subcutaneous injections given once every 3 months.

DRUG

Sunitinib Malate

Starting dose of 12.5 mg by mouth daily for 4 weeks

DRUG

Casodex

Once a day by mouth for 2 weeks.

RADIATION

Radiation Therapy (RT)

Radiation treatment once daily over a period of 8 weeks.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Paul Corn, MD, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00631527 on ClinicalTrials.gov